Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European Lung Cancer Congress 2019 /
The role of afatinib in patients with EGFR NSCLC

10th - 13th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.04.19
Views: 957

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

Dr Antonio Passaro speaks to ecancer at the European Lung Cancer Congress 2019.

He outlines the Phase III trial which evaluates the role of afatinib in patients with EGFR NSCLC.

Dr Passaro describes the data so far, and also some of the future prospects for the research, including a comparison of clinical trail and clinical practise data.

He finishes by outlining the toxicity profile of the combination.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation